Physician profile
Stephen P Datu
NPI 1386746287
$10,714.42
in general payments reported to CMS, 2019-2025
43 companies · $1,711 in 2025
The $1,711 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,417 · 2020: $2,032 · 2021: $2,027 · 2022: $1,074 · 2023: $1,147 · 2024: $1,308 · 2025: $1,711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,165.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,841.78 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Pfizer INC. | $1,358.94 | 2019-2025 | |
| Glaxosmithkline, LLC. | $644.74 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $613.07 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $599.02 | 2019-2025 | Farxiga, Airsupra |
| Allergan, INC. | $570.27 | 2019-2020 | |
| Amgen INC. | $543.21 | 2020-2025 | Otezla, Repatha, Otezla |
| Novo Nordisk INC | $445.66 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Kowa Pharmaceuticals America, INC. | $333.94 | 2019-2023 | Livalo, Seglentis |
| Lilly USA, LLC | $330.89 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Vanda Pharmaceuticals INC. | $239.59 | 2019-2025 | Fanapt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.91 | 2020-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $227.74 | 2020-2025 | Xifaxan, Trulance |
| Arbor Pharmaceuticals, INC. | $198.93 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $164.70 | 2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Datu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.